Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | TK1 | P04183 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27203667 | 1.00 | TYMP (0.41) | TYMPHPGDMAPK1TK1 | |
| SCHEMBL7529489 | 0.82 | HPGD (0.43) | TYMPHPGDMAPK1TK1 | |
| SCHEMBL5349908 | 0.82 | TK1 (0.39) | HPGDTK1 | |
| SCHEMBL27203679 | 0.81 | TK1 (0.34) | HPGDTK1 | |
| SCHEMBL27207170 | 0.81 | TK1 (0.34) | HPGDTK1 | |
| SCHEMBL6065649 | 0.79 | HPGD (0.42) | TYMPHPGDMAPK1TK1 | |
| SCHEMBL5370203 | 0.79 | TYMP (0.35) | TYMPHPGDTK1 | |
| SCHEMBL23957704 | 0.78 | TNKS (0.34) | TYMPHPGDMAPK1TK1 | |
| SCHEMBL18788917 | 0.76 | HPGD (0.40) | HPGDMAPK1TK1 | |
| SCHEMBL24540235 | 0.76 | TYMP (0.39) | TYMPHPGDMAPK1TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132628-A1 | OLIGONUCLEOTIDE ANALOGUE THERAPEUTICS FOR TREATMENT OF NEUROMUSCULAR DISEASE | NEUBASE THERAPEUTICS, INC. | 2024-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132628-A1 | OLIGONUCLEOTIDE ANALOGUE THERAPEUTICS FOR TREATMENT OF NEUROMUSCULAR DISEASE | SMN1; SMN2, POLRMT, TARDBP | TYMP 138/4885HPGD 4487/4885MAPK1 4676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.